Survival after sorafenib: Expect the unexpected

Journal of Hepatology

Volumn 60, Issue 2, 2014, Pages 243-244

  Finn, Richard S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; BRIVANIB; EVEROLIMUS; SCATTER FACTOR RECEPTOR; SORAFENIB; TIVANTINIB; UFT;

ADVANCED CANCER; CANCER GROWTH; CANCER SURVIVAL; EDITORIAL; HEPATITIS B VIRUS; HISTORY; HUMAN; LIVER CELL CARCINOMA; LIVER DISEASE; LIVER FUNCTION; LIVER INJURY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT SELECTION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POPULATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); TAIWAN;

CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; LIVER NEOPLASMS; MALE;

EID: 84892520246     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2013.10.031     Document Type: Editorial

References (11)

1. J.M. Llovet, S. Ricci, V. Mazzaferro, P. Hilgard, E. Gane, and J.F. Blanc et al. Sorafenib in advanced hepatocellular carcinoma N Engl J Med 359 2008 378 390
2. J.M. Llovet, T. Decaens, J.L. Raoul, E. Boucher, M. Kudo, and C. Chang et al. Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study J Clin Oncol 31 2013 3509 3516
3. Available from: < http://www.novartis.com/newsroom/media-releases/en/ 2013/1721562.shtml > [cited August 7, 2013].
4. R.S. Finn, Y.K. Kang, M. Mulcahy, B.N. Polite, H.Y. Lim, and I. Walters et al. Phase II, open-label study of brivanib as second-line therapy in patients with advanced hepatocellular carcinoma Clin Cancer Res 18 2012 2090 2098
5. A.X. Zhu, T.A. Abrams, R. Miksad, L.S. Blaszkowsky, J.A. Meyerhardt, and H. Zheng et al. Phase 1/2 study of everolimus in advanced hepatocellular carcinoma Cancer 117 2011 5094 5102
6. H.S. Shiah, C.Y. Chen, C.Y. Dai, C.F. Hsiao, Y.J. Lin, and W.C. Su et al. Randomised clinical trial: comparison of two everolimus dosing schedules in patients with advanced hepatocellular carcinoma Aliment Pharmacol Ther 37 2013 62 73
7. A.L. Cheng, Y.K. Kang, Z. Chen, C.J. Tsao, S. Qin, and J.S. Kim et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial Lancet Oncol 10 2009 25 34
8. Shao Y-Y, Wu C-H, Lu L-C, Chan S-Y, Ma Y-Y, Yen F-C, et al. Prognosis ofpatients with advanced hepatocellular carcinoma who failed first-linesystemic therapy. J Hepatol 2014;60:313-318.
9. A. Forner, J.M. Llovet, and J. Bruix Hepatocellular carcinoma Lancet 379 2012 1245 1255
10. M. Reirg, J. Rimola, F. Torres, A. Darnell, C.R. Lope, and A. Forner et al. Post-progression survival of patients with advanced hepatocellular carcinoma. Rationale for second-line trial design Hepatology 2013 [Epub ahead of print]
11. A. Santoro, L. Rimassa, and I. Borbath Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomized, placebo-controlled phase 2 study Lancet Oncol 14 2013 55 63